Johnson & Johnson CEO Rules Out Obesity Market Entry, Focuses on Cancer and AI
Joaquin Duato states the firm prioritizes oncology and dementia research while noting artificial intelligence's potential to accelerate drug discovery.
This story has stopped developing; this page is its permanent record. More from that day
The odds
Each tick is a source publishing on this story
Price data
| Time | Chance of yes |
|---|---|
| now | 49% |
| 10 Oct, 14:27 UTC | 49% |
| 10 Oct, 11:04 UTC | 48% |
| 10 Oct, 09:08 UTC | 44% |
| 9 Oct, 23:32 UTC | 50% |
| 9 Oct, 19:37 UTC | 49% |
| 9 Oct, 18:28 UTC | 48% |
| 9 Oct, 14:31 UTC | 51% |
| 9 Oct, 03:40 UTC | 49% |
| 9 Oct, 01:42 UTC | 50% |
| 9 Oct, 00:03 UTC | 48% |
| 8 Oct, 23:10 UTC | 47% |
| 8 Oct, 18:46 UTC | 52% |
| 8 Oct, 17:16 UTC | 49% |
| 8 Oct, 14:44 UTC | 47% |
| 7 Oct, 13:26 UTC | 54% |
The story so far
1 publisher has covered this in 1 article since 8 Oct 2026. Bloomberg Markets published first, on 8 October at 14:25 UTC.
One prediction market prices this story:
- AI / Artificial Intelligence — the market puts it at 49%, with $215 traded in the last 24 hours, closing 31 Mar 2027. The market resolves to Yes if any Johnson & Johnson representative mentions AI or artificial intelligence during the upcoming earnings call, including the question-and-answer session. It resolves to No if no such mention occurs. Readers often mistakenly believe that general discussions about technology or innovation count as AI references, but only explicit mentions of "AI" or "artificial intelligence" qualify.
Odds are the market's probability that the outcome happens, updated every few minutes. They are information about what traders expect, not a forecast we make and not investment advice.
Sources
Every article we clustered into this story. Headlines link to the publisher.
Markets on this story
- Kalshi AI / Artificial Intelligence 49% −2
Does the market have this right?
Wrong market?
Have your say
Your call. How does this end?
Free, no money involved. Calls are scored against the market's price when you make them, so backing an underdog that wins scores most. Leaderboard · Your calls
Email me when the odds move
In this story
- Joaquin Duato
- Johnson & Johnson